The burden of drug overdose deaths among correctional populations: implications for interventions.
作者信息
Fischer Benedikt, Moghimi Elnaz, Weekes John
机构信息
Faculty of Health Sciences (Fischer), Simon Fraser University, Vancouver; Research & Graduate Studies (Fischer), University of the Fraser Valley, Abbotsford, BC; Waypoint Research Institute, Waypoint Centre for Mental Health (Fischer, Moghimi), Penetanguishene, Ont.; Department of Psychiatry (Fischer), University of Toronto, Toronto, Ont.; Department of Psychiatry (Moghimi), Queen's University, Kingston, Ont.; Canadian Centre on Substance Use and Addiction (Weekes); Department of Psychology (Weekes), Carleton University, Ottawa, Ont.
出版信息
CMAJ. 2024 Dec 15;196(43):E1414-E1416. doi: 10.1503/cmaj.241661.
Abstract
摘要
相似文献
1
The burden of drug overdose deaths among correctional populations: implications for interventions.惩教人群中药物过量死亡的负担：对干预措施的影响。
CMAJ. 2024 Dec 15;196(43):E1414-E1416. doi: 10.1503/cmaj.241661.
2
Characteristics of inmates witnessing overdose events in prison: implications for prevention in the correctional setting.监狱中目睹过量用药事件的囚犯特征：对惩教环境中预防工作的启示
Harm Reduct J. 2009 Jul 9;6:15. doi: 10.1186/1477-7517-6-15.
3
Feasibility and effectiveness of extended-release buprenorphine (XR-BUP) among correctional populations: a systematic review.缓释丁丙诺啡（XR-BUP）在惩教人群中的可行性和有效性：一项系统评价。
Am J Drug Alcohol Abuse. 2024 Sep 2;50(5):567-586. doi: 10.1080/00952990.2024.2360984. Epub 2024 Jun 28.
4
Addressing excess risk of overdose among recently incarcerated people in the USA: harm reduction interventions in correctional settings.应对美国近期刑满释放人员用药过量的额外风险：惩教场所的减少伤害干预措施。
Int J Prison Health. 2017 Mar 13;13(1):25-31. doi: 10.1108/IJPH-08-2016-0039.
5
Naloxone in Correctional Facilities for the Prevention of Opioid Overdose Deaths.惩教设施中用于预防阿片类药物过量死亡的纳洛酮。
J Correct Health Care. 2022 Feb;28(1):66-67. doi: 10.1089/jchc.2021.29008.NCCHC. Epub 2021 Dec 30.
6
Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.扩大监狱中阿片类药物使用障碍（MOUD）药物的获取途径：一项综合项目评估。
J Subst Use Addict Treat. 2024 Jun;161:209248. doi: 10.1016/j.josat.2023.209248. Epub 2023 Dec 9.
7
No decline in drug overdose deaths in Norway: An ecological approach to understanding at-risk groups and the impact of interventions.挪威药物过量死亡人数未下降：一种理解高危群体及干预措施影响的生态学方法
Nordisk Alkohol Nark. 2024 Feb;41(1):111-130. doi: 10.1177/14550725231195413. Epub 2023 Sep 28.
8
The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.在全州范围内的惩教系统中实施阿片类药物使用障碍治疗药物和 COVID-19 对治疗参与度、释放后继续治疗和药物过量的影响。
J Subst Use Addict Treat. 2023 Sep;152:209103. doi: 10.1016/j.josat.2023.209103. Epub 2023 Jun 11.
9
Characterizing and combating the opioid epidemic in the Los Angeles County jail system.剖析并应对洛杉矶县监狱系统中的阿片类药物泛滥问题。
J Subst Use Addict Treat. 2023 Apr;147:208984. doi: 10.1016/j.josat.2023.208984. Epub 2023 Feb 20.
10
Economic burden of drug overdose deaths before and during the COVID-19 pandemic in the USA.美国 COVID-19 大流行前后药物过量死亡的经济负担。
J Comp Eff Res. 2022 Jun;11(9):643-648. doi: 10.2217/cer-2021-0314. Epub 2022 May 6.
本文引用的文献
1
Cost-benefit analysis of Canada's Prison Needle Exchange Program for the prevention of hepatitis C and injection-related infections.加拿大监狱针头交换项目预防丙型肝炎及注射相关感染的成本效益分析。
CMAJ. 2024 Dec 15;196(43):E1401-E1412. doi: 10.1503/cmaj.240648.
2
Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis.干预措施以减少监禁人群中与药物使用相关的危害：系统评价和荟萃分析。
Lancet Public Health. 2024 Sep;9(9):e684-e699. doi: 10.1016/S2468-2667(24)00160-9.
3
Rates and causes of death after release from incarceration among 1 471 526 people in eight high-income and middle-income countries: an individual participant data meta-analysis.在八个高收入和中等收入国家中，从监禁中释放后 1471526 人的死亡率和死亡原因：一项个体参与者数据荟萃分析。
Lancet. 2024 May 4;403(10438):1779-1788. doi: 10.1016/S0140-6736(24)00344-1. Epub 2024 Apr 10.
4
Prescribed safer opioid supply: A scoping review of the evidence.规定更安全的阿片类药物供应：证据的范围综述。
Int J Drug Policy. 2024 Mar;125:104339. doi: 10.1016/j.drugpo.2024.104339. Epub 2024 Feb 9.
5
Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.风险缓解指导下阿片类药物和兴奋剂配给对双重公共卫生紧急情况下的死亡率和急性护理就诊的影响：回顾性队列研究。
BMJ. 2024 Jan 10;384:e076336. doi: 10.1136/bmj-2023-076336.
6
Burden of opioid toxicity death in the fentanyl-dominant era for people who experience incarceration in Ontario, Canada, 2015-2020: a whole population retrospective cohort study.2015-2020 年加拿大安大略省监禁人群中芬太尼主导时期阿片类药物毒性死亡负担：一项全人群回顾性队列研究。
BMJ Open. 2023 May 10;13(5):e071867. doi: 10.1136/bmjopen-2023-071867.
7
Anticipated Barriers to Sustained Engagement in Treatment With Medications for Opioid Use Disorder After Release From Incarceration.监禁释放后，持续使用药物治疗阿片类药物使用障碍过程中预期的参与障碍。
J Addict Med. 2023;17(1):54-59. doi: 10.1097/ADM.0000000000001029. Epub 2022 Aug 2.
8
Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada.加拿大安大略省从联邦监禁中释放到社区的个体参与阿片类激动剂治疗（OAT）的障碍和促进因素。
Int J Qual Stud Health Well-being. 2022 Dec;17(1):2094111. doi: 10.1080/17482631.2022.2094111.
9
The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis.监狱人群中合并严重精神疾病和物质使用障碍的患病率：系统评价和荟萃分析。
Lancet Public Health. 2022 Jun;7(6):e557-e568. doi: 10.1016/S2468-2667(22)00093-7.
10
Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.2015-2018 年加拿大安大略省省级监狱中阿片类激动剂治疗处方率：一项重复横断面分析。
BMJ Open. 2021 Nov 18;11(11):e048944. doi: 10.1136/bmjopen-2021-048944.
Zotero 插件